Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609607 · ClinicalTrials.gov registry record · Phase 2
Treating Anorectal Dysfunction in MS
A Phase 2 study, sponsored by David Levinthal.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02609607 is a Phase 2 study that was terminated before completion, run by David Levinthal. The registered enrollment target is 11 participants.
The verdict
NCT02609607, a Phase 2 study, was terminated before completion, sponsored by David Levinthal.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The investigators seek to test whether incorporating the scheduled dosing of a bisacodyl 10 mg rectal suppository every other day improves bowel-related symptoms in patients with multiple sclerosis. Patients will be randomized to receive either a placebo suppository or bisacodyl suppository dosed every other day for 4 weeks.
Interventions
- OTHER Placebo
- DRUG Bisacodyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609607
The ClinicalTrials.gov registry entry for NCT02609607 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Levinthal, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02609607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02609607 about?
NCT02609607 is a clinical study titled "Treating Anorectal Dysfunction in MS". The investigators seek to test whether incorporating the scheduled dosing of a bisacodyl 10 mg rectal suppository every other day improves bowel-related symptoms in patients with multiple sclerosis. Patients will be randomized to receive either a placebo suppository or bisacodyl suppository dosed ev...
What is the current status of trial NCT02609607?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-06. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02609607?
The interventions under investigation include: Placebo (OTHER), Bisacodyl (DRUG).
Who is sponsoring clinical trial NCT02609607?
This trial is sponsored by David Levinthal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.